On 1 July 2020, Pepper Hamilton and Troutman Sanders merged to create Troutman Pepper Hamilton Sanders LLP, or ‘Troutman Pepper,’ with 1,100 attorneys in 23 offices across the country. Our antitrust attorneys guide clients through the complex and highly regulated challenges of business competition issues in the United States as well as abroad. We represent clients ranging from Fortune 100 companies to new entrants in a broad range of industries, including software, high-tech, building materials, chemicals, energy, publishing, media and entertainment, transportation, telecommunications, sports, agriculture, pharmaceuticals, medical devices and healthcare. Our successes include landmark court decisions, obtaining clearance for mergers and acquisitions, and resolving civil and criminal government investigations at the state and federal levels. We regularly advocate for clients before US antitrust enforcement agencies such as the Department of Justice and the Federal Trade Commission. We have been involved in landmark cases and large-scale litigations involving agricultural cooperatives and trade associations, the pharmaceutical industry, hospitals and health systems, flat glass, trucks, autos and auto parts, the publishing industry, the New York construction industry, the battery business and the largest patent assertion entity. We have developed a particular level of knowledge in litigating antitrust claims concerning innovative technologies, and our antitrust and intellectual property teams have successfully collaborated to provide technical knowledge and fierce advocacy in court. In the energy space, we have successfully represented public utilities and energy marketers in antitrust cases in both regulated and deregulated markets, including leading cases concerning independent power, qualifying facilities and stateaction immunity. In the pharmaceutical sector, we also have experience defending clients in patent-antitrust cases, including against allegations of ‘sham’ patent litigation, fraud on the Patent and Trademark Office, improper Orange Book listings and anticompetitive settlement agreements with generics.